GGrantIndex
Sort

64,565 grants matching drug discovery

Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)

$991,375
Larry Zeitlin · Mapp Biopharmaceutical, Inc. · U01 · FY2009 · AI

A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention

$991,290
Kriston Lyle McGary · Genetic Networks, Llc · R44 · FY2019 · TR

Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS

$991,186
Thomas Edward Smithgall · Fox Chase Chemical Diversity Center, Inc · R42 · FY2017 · GM

Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases

$990,946
Jay L Rothstein · Immunext, Inc. · R44 · FY2021 · AI

Therapeutic Antibodies for CMV

$990,935
Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2014 · AI

Therapeutic Antibodies for CMV

$990,877
Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2015 · AI

Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy

$990,691
Graham Beaton · Epigen Biosciences, Inc. · R44 · FY2022 · DK

AIR Option 2: Research Alliance - Ecosystem for Biophotonic Innovation (EBI) Building Sustainability

$990,573
Dennis L Matthews · University Of California-Davis · · FY2013 · TIP

Novel oxadiazols for the treatment of drug-resistant gram-positive bacteria

$990,528
Mayland F Chang · University Of Notre Dame · R01 · FY2014 · AI

Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia

$990,493
Christie G. Brouillette · University Of Alabama At Birmingham · U01 · FY2008 · AI

A method for preparing unbiased miRNA sequencing libraries (miR-ACS)

$990,251
Sergei A Kazakov · Somagenics, Inc. · R44 · FY2016 · HG

PDE4B Inhibitors For Treating Major Depression

$989,992
Mark E Gurney · Tetra Discovery Partners, Inc. · R44 · FY2014 · MH

Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort

$989,984
Eva L Feldman · University Of Michigan At Ann Arbor · R01 · FY2021 · NS

Informatics Tools for High-Throughput Sequences Data Analysis

$989,800
Eric Banks · Broad Institute, Inc. · U01 · FY2014 · HG

IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

$989,205
Patrick Beardsley · Virginia Commonwealth University · N01 · FY2019 · DA

Improved bacterial strains for therapeutic DNA and protein production

$989,190
Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2009 · GM

Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

$988,940
Russell Dahl · Neurodon Llc · R42 · FY2020 · AG

Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases

$988,840
Robert G Lowery · Bellbrook Labs, Llc · R44 · FY2021 · AI

Developmental Funds

$988,726
Stanton L Gerson · Case Western Reserve University · P30 · FY2021 · CA

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)

$988,679
Kenneth W Turteltaub · University Of Calif-Lawrnc Lvrmr Nat Lab · P41 · FY2019 · GM

InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation

$988,414
Bill Thelin · Altis Biosystems, Inc. · R44 · FY2023 · TR

Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis

$988,293
Michelle M. Butler · Microbiotix, Inc · R44 · FY2015 · AI

Mechanisms of Cell Regulation and Manipulation by the Ubiquitin System

$988,057
Mark Hochstrasser · Yale University · R35 · FY2025 · GM

Novel Biguanides to Treat Type 2 Diabetes

$987,938
Ken W Batchelor · Novatarg, Inc. · R44 · FY2016 · DK

Leveraging natural phenotypic variations of heterogenous ALS populations-in-a-dish to enable scalable drug discovery

$987,822
Justin Kawika Ichida · University Of Southern California · R01 · FY2023 · NS